The Omicron variant of the coronavirus does not have a negative effect on cardiovascular health in young adults who have been vaccinated, a small study suggests. Additionally, women should not delay routine mammograms after receiving a COVID-19 mRNA vaccine, experts now say.

Merck

Researchers studying Merck & Co. Inc.’s cancer drug Keytruda for HIV patients who also have cancer say the immunotherapy may help displace the virus from human immune cells, offering an intriguing area of study for treatment of chronic HIV infection.

AbbVie exercised an exclusive right to acquire TeneoOne, an affiliate of TeneoBio, and the company’s lead asset TNB-383B for relapsed or refractory multiple myeloma (R/R MM). 

A study from the Icahn School of Medicine at Mount Sinai shows how cancer can fool immune cells, which normally repair the body, into actually helping develop the disease. 

Current guidelines for screening U.S. blood donors for symptoms of COVID-19 and for a history of recent infections are effectively protecting the blood supply from contamination with the new coronavirus, researchers say.

Months after recovery from mild Covid-19 – when antibody levels in the blood have declined – immune cells in bone marrow remain ready to pump out new antibodies against the coronavirus, researchers reported on May 24 in Nature. And according to a new U.S. study, young children appear to be significant carriers of more contagious variants of the new coronavirus, such as the ones identified in the UK and in California.

A new study by researchers at the University College London (UCL) published in Lancet Infectious Diseases finds that although the U.K. variant of SARS-CoV-2 known as B.1.1.7 is more transmissible than the wild-type, original Wuhan strain, it is likely not more deadly.

Paris-based Sanofi bought Cambridge, Massachusetts-based Tidal Therapeutics in a deal totaling $470 million.

Immunai, a company comprehensively mapping the immune system, announced a collaboration with leading life science technology company 10x Genomics.

Europe’s health regulator started a real-time review of Johnson & Johnson’s Covid-19 vaccine candidate after preliminary results showed that the shot triggered the production of antibodies and immune cells against the virus.